000 | 01705 a2200505 4500 | ||
---|---|---|---|
005 | 20250514032303.0 | ||
264 | 0 | _c20020926 | |
008 | 200209s 0 0 eng d | ||
022 | _a0114-5916 | ||
024 | 7 |
_a10.2165/00002018-200225040-00005 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aClaessens, Angela A M C | |
245 | 0 | 0 |
_aDeterminants of headache in lansoprazole users in The Netherlands: results from a nested case-control study. _h[electronic resource] |
260 |
_bDrug safety _c2002 |
||
300 |
_a287-95 p. _bdigital |
||
500 | _aPublication Type: Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _a2-Pyridinylmethylsulfinylbenzimidazoles |
650 | 0 | 4 | _aAdolescent |
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aAge Factors |
650 | 0 | 4 | _aAged |
650 | 0 | 4 | _aCase-Control Studies |
650 | 0 | 4 | _aChild |
650 | 0 | 4 | _aChild, Preschool |
650 | 0 | 4 | _aDose-Response Relationship, Drug |
650 | 0 | 4 | _aDrug Interactions |
650 | 0 | 4 |
_aEnzyme Inhibitors _xadverse effects |
650 | 0 | 4 |
_aHeadache _xchemically induced |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aIncidence |
650 | 0 | 4 | _aInfant |
650 | 0 | 4 | _aLansoprazole |
650 | 0 | 4 | _aMatched-Pair Analysis |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 | _aNetherlands |
650 | 0 | 4 |
_aOmeprazole _xadverse effects |
650 | 0 | 4 | _aRisk Factors |
650 | 0 | 4 | _aSurveys and Questionnaires |
700 | 1 | _aHeerdink, Eibert R | |
700 | 1 | _avan Eijk, Jacques T H M | |
700 | 1 | _aLamers, Cornelis B H W | |
700 | 1 | _aLeufkens, Hubert G M | |
773 | 0 |
_tDrug safety _gvol. 25 _gno. 4 _gp. 287-95 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.2165/00002018-200225040-00005 _zAvailable from publisher's website |
999 |
_c11893392 _d11893392 |